columbia laboratories inc
(CBRX:NASDAQ CM)

Executive Profile*

Background*

Mr. Frank Charles Condella, Jr. has been the Chief Executive Officer and President of Columbia Laboratories Inc. since May 2010. Mr. Condella served as an Interim Chief Executive Officer of Columbia Laboratories Inc. from December 2009 to May 2010. Mr. Condella served as Chief Executive Officer of SkyePharma plc from March 1, 2006 to September 1, 2008. Mr. Condella served as Managing Director of Norton Healthcare Limited since July 2002. Mr. Condella served as the Chief ... Executive Officer and President of Mayne Pharma (USA) Inc. He joined SkyePharma plc in March 2006. He served as Managing Director at IVAX Pharmaceuticals UK Ltd. and Vice President of the Specialty Business for F. Hoffman-La Roche Ltd. He served as Vice President and General Manager of Lederle Standard Products at American Home Products. From January 2000 to October 2001, he served as President and Chief Executive Officer of Faulding Pharmaceuticals Co, F.H. Faulding Ltd. and Adelaide S.A. Australia. He served as Vice President of Roche Laboratories Inc. from January 1996 to January 2000. Mr. Condella has over 25 years' commercial experience in the pharmaceutical industry, having worked for several major international companies. He served as President of Pharmaceuticals European Operations for IVAX Corp., from 2002 to February 28, 2006. He has been the Chairman of the Board at SkyePharma plc since January 1, 2010. He has been Independent Director of Columbia Laboratories Inc., since March 10, 2009. He has been Non Executive Director of SkyePharma plc since November 1, 2008. He has been a Member of the Supervisory Board of Polfa Kutno S.A. since February 2005. Mr. Condella served as Non Executive Director of Fulcrum Pharma plc since September 26, 2008. He serves as a Director of SkyePharma Production SAS, SkyePharma (Jersey) Limited, SkyePharma AB, SkyePharma Holding Inc., SkyePharma US Inc. and Krypton Limited. He served as Executive Director of SkyePharma plc since April 2006 until November 1, 2008. Mr. Condella served as a Director of Thomas Kerfoot & Co Limited, IVAX Pharma GmbH, IVAX International (Luxembourg) Sarl, IVAX Farma BV, IVAX International BV, IVAX Pharma Poland sp z.o.o, Kutnowskie Zaklady Farmaceutyczne, "Polfe" Spolka Akcy Jna, Galena Pharma Limited, IVAX Scandinavia AB, IVAX Pharmaceuticals South Africa (Proprietary) Limited, IVAX Farmaceutici S.r.l, IVAX India (Pvt) Ltd., Becpharm Limited, HN Norton & Co Limited, IVAX Europe Limited, IVAX Finland OY, IVAX Healthcare Limited, IVAX Healthcare UK Limited, IVAX Laboratories Limited, IVAX Laboratories UK Limited, IVAX Pharmaceuticals Limited, IVAX Pharmaceurticals UK Limited, IVAX UK Limited, K Pharmaceuticals Limited, Norton (Waterford) Limited, Norton Healthcare (1998) Limited, Norton Healthcare (1999) Limited, Norton Pharmaceuticals Limited, Pharmexco Limited, Steripak Limited, Waverley Pharmaceutical Limited and Baker Norton Limited. Mr. Condella holds an MBA from the Graduate School of Business, Northeastern University in Boston and a B.S. in Pharmacy from the College of Pharmacy and Allied Health, Northeastern University, Boston.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
CBRX:US	$0.62 USD	0.00

COMPETITOR COMPENSATION